EIDX Insider Trading Activity and SEC Form 4 Filings
EIDX insider trading summary
No open-market insider purchases or sales of Eidos Therapeutics, Inc. (EIDX) have been reported on SEC Form 4 in the past 12 months.
Latest EIDX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 26, 2021 | BridgeBio Pharma, Inc. | 10% Owner | Buy | $0 (14,428,836 @ $0.00) |
| Jan 13, 2021 | Uma Sinha | Chief Scientific Officer | Sell | $251K (2,000 @ $125.35) |
| Jan 13, 2021 | Uma Sinha | Chief Scientific Officer | Sell | $70K (572 @ $122.27) |
| Jan 13, 2021 | Uma Sinha | Chief Scientific Officer | Sell | $185K (1,498 @ $123.48) |
| Jan 13, 2021 | Uma Sinha | Chief Scientific Officer | Sell | $615K (4,934 @ $124.72) |
| Jan 13, 2021 | Uma Sinha | Chief Scientific Officer | Sell | $84K (696 @ $121.11) |
| Jan 13, 2021 | Uma Sinha | Chief Scientific Officer | Sell | $38K (300 @ $126.39) |
| Jan 12, 2021 | Franco Valle | Senior Vice President, Finance | Sell | $219K (1,747 @ $125.44) |
| Jan 11, 2021 | Franco Valle | Senior Vice President, Finance | Sell | $188K (1,500 @ $125.61) |
| Dec 15, 2020 | Cameron Turtle | Chief Business Officer | Sell | $395K (3,493 @ $112.97) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.